Hepatorenal Syndrome News and Research

RSS

A growing burden of alcoholic hepatitis

A recent study published in the journal Medical Clinics of North America discussed the diagnosis, treatment, and pathophysiology of alcoholic hepatitis (AH).

21 Feb 2023

SBIR grant awarded to develop treatment for alcoholic liver disease-associated hepatorenal syndrome

The Institute of Human Virology (IHV) at the University of Maryland School of Medicine and MitoPower LLC were awarded an SBIR (Small Business Innovation Research) grant of up to $6.5 million over five years from the National Institutes of Health's National Institute on Alcohol Abuse and Alcoholism.

9 Nov 2021

New set of recommendations for managing liver failure in the ICU

For critical care specialists, hepatic failure poses complex challenges unlike those of other critical illnesses.

16 Feb 2020

Study finds lower levels of liver decompensation in pregnant women with cirrhosis

Data from a new study presented this week at The Liver Meeting – held by the American Association for the Study of Liver Diseases and funded by the AASLD Foundation – found that less than two percent of pregnant women with cirrhosis had liver decompensation within one year of delivery, and their odds of decompensation is much lower than non-pregnant women with cirrhosis.

10 Nov 2019

Drinking during late adolescence could be first step to liver problems in adulthood

Alcohol is the leading cause of liver cirrhosis and liver-related deaths. Results of a large long-term study in Sweden have confirmed that drinking during late adolescence could be the first step towards liver problems in adulthood and that guidelines for safe alcohol intake in men might have to be revised downwards, reports the Journal of Hepatology.

22 Jan 2018

Cumberland initiates clinical development of Boxaban (ifetroban) oral capsule for AERD treatment

Cumberland Pharmaceuticals Inc. today announced an expansion of its pipeline with a new Phase II development program. The Company has initiated the clinical development of Boxaban (ifetroban) oral capsule for the treatment of aspirin-exacerbated respiratory disease (AERD).

11 Feb 2015

Combination drug does not improve survival in patients with severe alcoholic hepatitis

Four weeks of treatment with a combination of the drug pentoxifylline and the corticosteroid prednisolone did not improve 6-month survival compared with prednisolone alone in 270 patients with severe alcoholic hepatitis, according to a study in the September 11 issue of JAMA.

11 Sep 2013

PharmaIN receives FDA orphan-drug designation for terlipressin to treat ascites

PharmaIN Corporation and LAT Pharma LLC today announced that the US Food and Drug Administration (FDA) has granted their request for orphan-drug designation for terlipressin for the treatment of ascites due to all etiologies except for cancer.

7 Jan 2013

TGA approves Ikaria’s LUCASSIN to treat Hepatorenal Syndrome Type 1

Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies for critically ill patients, announced today the approval of LUCASSIN (terlipressin) by the Therapeutic Goods Administration (TGA) of Australia.

24 Apr 2012

Cumberland acquires Vanderbilt's ifetroban rights

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, today announced that it has entered into an agreement to acquire the rights to ifetroban, a new Phase II development product.

19 Apr 2011

Ikaria initiates enrollment in LUCASSIN Phase III trial for HRS Type 1

Ikaria, Inc. announced that it has enrolled the first patients in its pivotal Phase III trial for LUCASSIN® (terlipressin). The multi-center, randomized, placebo-controlled, double-blind trial is known as the REVERSE Trial.

30 Nov 2010

Recommendations available for managing ascites, SBP and hepatorenal syndrome

The peer reviewed guidelines will be available in the September 2010 issue, (Volume 53, No.3) of the Journal of Hepatology and online in advance of publication at http://www.ncbi.nlm.nih.gov/pubmed/20633946 . They also provide recommendations for the management of spontaneous bacterial peritonitis and hepatorenal syndrome, which often affect patients with cirrhosis.

3 Aug 2010

Extracorporeal liver support therapy valued as detoxification treatment option for patients with cirrhosis

Results from two studies presented today at the International Liver CongressTM 2010 have shown that treatment with extracorporeal devices may not confer a survival advantage for severe liver failure patients, despite positive dialysis effects. However, results among a small sub-group of patients show promise.

17 Apr 2010

Ikaria Holdings acquires NDA and IND application for LUCASSIN drug

Ikaria Holdings, Inc. announced today that it has acquired the New Drug Application (NDA) and the Investigational New Drug (IND) application to LUCASSIN® (terlipressin for injection) from Orphan Therapeutics, assuming all future development and ownership of the drug in North America and Australia.

31 Mar 2010

Transplantation of human mononuclear cells exerts a deleterious effect in rats with liver cirrhosis

The use of stem cells in regenerative medicine is not always beneficial for human health, it may even be harmful according to a work done by the universities of Granada and León. Scientists have demonstrated that transplantation of human mononuclear cells isolated from umbilical cord blood exerted a deleterious effect in rats with liver cirrhosis.

12 Nov 2009

Global prevalence of kidney failure among critically ill patients

A multinational study has found that 5 to 6 percent of patients in intensive care units experience acute kidney failure, and about 60 percent of these patients die in the hospital, according to an article in the August 17 issue of JAMA: The Journal of the American Medical Association.

18 Aug 2005

GenoMed to be awarded new patent, for treating acute kidney failure without dialysis

GenoMed announced today that the US Patent Office has allowed claims and will be following up with an issued patent shortly on the Company's protocol to treat acute kidney failure with a drug rather than the dialysis machine.

14 Jun 2005

Fast Track designation for Terlipressin in type 1 hepatorenal syndrome

Protein Design Labs, Inc. and privately held Orphan Therapeutics, LLC today reported that the U.S. Food and Drug Administration (FDA) has granted Fast Track status to the development of terlipressin for the treatment of patients with type 1 hepatorenal syndrome (HRS).

20 Apr 2005

Short-term use of selective COX-2 inhibitors may be safe for patients with cirrhosis of the liver

Short-term use of selective COX-2 inhibitors may be safe for patients with cirrhosis of the liver, according to a recent study that compared the effects of celecoxib, naproxen, and a placebo on cirrhotic patients in a double-blind randomized controlled study.

22 Feb 2005